

Certificate of Analysis

BTK (E41K), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-773, 14-773-K, 14-773M

Parent Lot # D7MN055N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, full-length, human BTK containing the E41K mutation. Expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked agammaglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, *et al.*, *Immunity*,(1995);2:451-460 and Baraldi, E., *et al.*, *Structure*,(1999);7:449-460). Purity 62% by SDS-PAGE and Coomassie blue staining. MW = 78.4kDa.

Specific Activity (Parent lot# D7MN055N): 48U/mg, where one unit of BTK (E41K) activity is defined as 1nmol phosphate incorporated into 300µM LKBtide (LSNLYHQGKFLQTFCSPLYRRR) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 2.88mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 28–350ng of this lot of enzyme phosphorylated 300µM LKBtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as BTK with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of active BTK (E41K).

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **LKBtide (LSNLYHQGKFLQTFCGSPLYRRR):** Use at a final assay concentration of 300 μ M. Prepare a 3mM stock and add 2.5 μ l of stock per assay point.
3. **NaCl:** Use at a final assay concentration of 100mM. Make a 3M stock. Add 0.83 μ l of stock per assay point.
4. **Triton X-100:** Make up a 10% (w/v) stock. Add 2.5 μ l of stock per assay point.
5. **BTK (E41K), active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 28–350ng per assay point.
6. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **LKBtide**.
3. Add **2.5 μ l (28–350ng) BTK (E41K), active**.
4. Add 0.83 μ l of 3M NaCl
5. Add 2.5 μ l of 10% (w/v) Triton X-100.
6. Add 1.67 μ l of dH₂O.
7. Add 10 μ l of diluted [γ -³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
10. Transfer a 10 μ l aliquot onto the appropriate area of a P30 Filtermat.
11. Wash the filtermat three times for 5 minutes with 50mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

BTK (E41K) Sequence Information

<u>Protein</u>	human BTK (E41K)
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M16 of the recombinant protein is equivalent to M1 of human BTK
<u>Accession number</u>	GenBank NM_000061

Recombinant BTK amino acid sequence:

```

1  MHHHHHHEFEK  GLRRRMAAVI  LESIFLKRISQ  QKKKTSPLNF  KKRLFLLTVH  KLSYYKYDFE
61  RGRRGSKKGS  IDVEKITCVE  TVVPEKNPPP  ERQIPRRGEE  SSEMEQISII  ERFPPYFQVV
121  YDEGPLYVFS  PTEELRKRWI  HQLKNVIRYN  SDLVQKYHPC  FWIDGQYLCC  SQTAKNAMGC
181  QILENRNGSL  KPGSSHRKTK  KPLPPTPEED  QILKKPLPPE  PAAAPVSTSE  LKKVVALYDY
241  MPMNANDLQL  RKGDEYFILE  ESNLPWWRAR  DKNQOQEGYIP  SNYVTEAEDS  IEMYEWYSKH
301  MTRSQAEOQL  KQEGKEGGFI  VRDSSKAGKY  TVSVFAKSTG  DPQGVIRHYV  VCSTPQSQYY
361  LAEKHLFSTI  PELINYHQHN  SAGLISRLKY  PVSQQKNAP  STAGLGYGSW  EIDPKDLTFL
421  KELGTGQFGV  VKYGKWRGQY  DVAIKMIKEG  SMSEDEFIEE  AKVMMNLSHE  KLVQLYGVCT
481  KQRPIFIITE  YMANGCLLNY  LREMRHRFQT  QQLLEMCKDV  CEAMEYLESK  QFLHRDLAAR
541  NCLVNDQGVV  KVSDFGLSRY  VLDDEYTSSV  GSKFPVRWSP  PEVLMYSKFS  SKSDIWAFGV
601  LMWEIYSLGK  MPYERFTNSE  TAEHIAQGLR  LYRPHLASEK  VYTIMYSCWH  EKADERPTFK
661  ILLSNILDVM  DEES

```

Recombinant BTK nucleotide sequence:

```

1  atgcatcatt  accatcacca  tgaattcaaa  ggcctacgtc  gacgaatggc  cgcagtgatt
61  ctggagagca  tctttctgaa  gcgatcccaa  cagaaaaaga  aaacatcacc  tctaaacttc
121  aagaagcgcc  tgtttctctt  gaccgtgcac  aaactctcct  actataagta  tgctttgtaa
181  cgtgggagaa  gaggcagtaa  gtaggggtca  atagatggtg  agaagatcac  ttgtggtgaa
241  acagtggttc  ctgaaaaaaaa  tcctcctcca  gaaagacaga  ttccgagaag  aggtgaagag
301  tccagtgaaa  tggagcaaat  ttcaatcatt  gaaaggttcc  cttatccctt  ccagggttgta
361  tatgatgaag  ggcctctcta  cgtcttctcc  ccaactgaag  aactaaggaa  gcgggtggatt
421  caccagctca  aaaacgtaat  ccggtacaac  agtgatctgg  ttcagaaaata  tcacccttgc
481  ttctggatcg  atgggcagta  tctctgctgc  tctcagacag  ccaaaaatgc  tatgggctgc
541  caaatttttg  agaacaggaa  tgggaagctta  aaacctggga  gttctcaccg  gaagacaaaa
601  aagcctcttc  ccccaacgcc  tgaggaggac  cagatcttga  aaaagccact  accgcctgag
661  ccagcagcag  caccagtctc  cacaagtgag  ctgaaaaagg  ttgtggccct  ttatgattac
721  atgccaatga  atgcaaatga  tctacagctg  cggaaaggtg  atgaatattt  tatcttgag
781  gaaagcaact  taccatggtg  gagagcacga  gataaaaatg  ggcaggaagg  ctacattcct
841  agtaactatg  tactgaagc  agaagactcc  atagaaatgt  atgagtggta  ttccaaacac
901  atgactcgga  gtcaggctga  gcaactgcta  aagcaagagg  ggaaagaagg  aggtttcatt
961  gtcagagact  ccagcaaac  tggcaaatat  acagtgtctg  tgtttgctaa  atccacaggg
1021  gaccctcaag  gggtgatacg  tcattatggt  gtgtgttcca  cacctcagag  ccagatttac
1081  ctggctgaga  agcacctttt  cagcaccatc  cctgagctca  ttaactacca  tcagcacaac
1141  tctgcaggac  tcatatccag  gctcaaatat  ccagtgtctc  aaaaaaacaa  gaatgcacct
1201  tccactgcag  gcctgggata  cggatcatgg  gaaattgatc  caaaggacct  gaccttcttg
1261  aaggactcgg  ggactggaca  atttggggta  gtgaagtatg  ggaaatggag  aggccagtac
1321  gacgtggcca  tcaagatgat  caaagaaggc  tccatgtctg  aagatgaatt  cattgaagaa
1381  gccaaagtca  tgatgaatct  ttcccatgag  aagctggctg  agttgtatgg  cgtctgcacc
1441  aagcagcgcc  ccatcttcat  catcactgag  tacatggcca  atggctgcct  cctgaactac
1501  ctgaggggaga  tgcgccaccg  cttccagact  cagcagctgc  tagagatgtg  caaggatgac

```

Certificate of Analysis

```
1561 tgtgaagcca tggaaatacct ggagtcaaag cagttccttc accgagacct ggcagctcga
1621 aactgtttgg taaacgatca aggagttggt aaagtatctg attcggcct gtccaggtat
1681 gtccctggatg atgaatacac aagctcagta ggctccaaat ttccagtccg gtgggtcccca
1741 ccggaagtcc tgatgtatag caagttcagc agcaaatctg acatttgggc ttttggggtt
1801 ttgatgtggg aaatttactc cctggggaag atgccatatg agagatttac taacagtgag
1861 actgctgaac acattgccca aggcctacgt ctctacaggc ctcatctggc ttcagagaag
1921 gtatatacca tcatgtacag ttggtggcat gagaaagcag atgagcgtcc cactttttaa
1981 attccttctga gcaatattct agatgtcatg gatgaagaat cctga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.